WHAT IS CLAIMED IS:

1. A compound having a structure that corresponds to the formula:



wherein

R_1, R_2, R_3 and R_4 are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R_1R_2 or R_3R_4, taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group;

R is a straight chained, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms;

Y is hydrogen, bromo, chloro or lower alkyl;

and X is selected from the group consisting of carboxy, hydroxy, acetoxy, alkanoyloxy, lower alkoxy, lower alkyl carbonyl, oximino, cyano, amino, $C(O)-R_5$ and $-C(O)C(O)-R_5$ wherein R_5 is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR_6R_7 wherein R_6 and R_7 are the same or different and are selected from the group consisting of hydrogen and lower alkyl, or R_6 or R_7 are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, hydroxy, acyloxy, benzyloxy, 2-hydroxy lower alkyl, lower alkyl carboxy, phenyl, substituted phenyl, pyridyl, thiazolyl, dihydrothiazolyl, 5-tetrazolyl,

$-OCO(CH_2)_nCOR_9$ wherein R_9 is -OH, -ONa, dialkylamino such as diethylamino and morpholino, and n is 2 or 3; $-OCOR_{10}$ wherein R_{10} is $-CH_2NR_{11}R_{12}$ wherein R_{11} and R_{12} are alkyl, such as methyl, cycloalkyl such as cyclohexyl, or together are a heterocyclic ring such as N-methylpiperazino, $-OCOR_{10}$ wherein R_{10} is $-CH_2Cl$, $-CH_2O$-loweralkyl or t-butyl, -CH-loweralkyl-CO_2-Q, wherein Q is lower alkyl or -H, acyl such as acetyl, propionyl or butyryl; $-NR_8OH$ wherein R_8 is hydrogen, -CO-loweralkyl, -CO-t-butyl, $-COC_7H_{15}$, -CO-phenyl, SO_2-lower alkyl, $-COCO_2$-lower alkyl, and -COCONHOH; $-NHR_{13}$ wherein R_{13} is hydrogen, -CO-lower alkyl, -CO-t-butyl, $-COC_7H_{15}$, -CO-phenyl, $-SO_2$-lower alkyl, $-COCO_2$-lower alkyl, -COCONHOH, $-COCO_2H$, COCON(lower alkyl)OH, and $PO(O\text{-lower alkyl})_2$; $-C(R_{14})=NNH$-2-thiazolino, $-CH(OH)R_{14}$ and $-C(O)R_{14}$ wherein R_{14} is hydrogen, lower alkyl, phenyl and t-butyl; $-C(=NOH)NH_2$ and $-C(=NH)N(OH)$-lower alkyl, ω-alkanoate and $O-NR_8R_9$ wherein R_8 and R_9 are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl;

with the provisos that:

(a) when Y is bromo or chloro, X is -COOH, $-CH_2OH$ or $-C(O)-R_5$ wherein R_5 is NR_6R_7 and R_6 is OH and R_7 is lower lakyl;

(b) at least one of R_1 and R_2 is other than hydrogen where (i) R-X is $(CH_2)_2CO_2H$ or $(CH_2)_2C(O)NHOH$, and (ii) R_3 and R_4 are 4-methoxy, 3-methoxy-4-hydroxy, 2-hydroxy and hydrogen and

(c) at least one of R_1 and R_2, or of R_3 and R_4 is other than hydrogen where R-X together contains three saturated carbon atoms linked together by carbon-carbon bonds; and pharmaceutically acceptable salts

thereof.

2. The compound according to claim 1 wherein R_2 and R_4 are hydrogen, and R_1 and R_3 are selected from the group consisting of halo, trifluoromethyl, lower alkyl and lower alkoxy.

3. The compound according to claim 2 wherein R is straight chained, saturated and contains three carbon atoms bonded together by carbon-carbon bonds.

4. The compound according to claim 3 wherein X is selected from the group consisting of hydroxy, carboxy, a carboxylate salt of a pharmaceutically acceptable cation, $C(O)-NR_6R_7$ wherein R_6 and R_7 are selected from the group consisting of hydrogen, hydroxyl, methyl, t-butyl, 2-hydroxyethyl and carboxymethyl.

5. The compound according to claim 2 wherein R is unsaturated and contains 2-16 carbon atoms.

6. The compound according to claim 5 wherein X is carboxyl or a salt thereof.

7. A compound having a structure that corresponds to the formula:



wherein R_1 and R_3 are selected from the group consisting of halo, trifluoromethyl, methyl and methoxy.

8. A compound having a structure that corresponds to the formula:



wherein R_1 and R_3 are selected from the group consisting of halo, trifluoromethyl, methyl, phenyl and methoxy; and

X is selected from the group consisting of carboxy, $C(O)-R_5$ wherein R_5 is selected from the group consisting of $N(CH_3)OH$, $N(t\text{-}C_4H_9)OH$, NHOH, $ONH(CH_3)$ and $ONH(t\text{-}C_4H_9)$.

~~9.~~ 2 A compound ~~of claim 1~~ which is 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-methylpropanamide.

~~10.~~ 9 A compound of claim ~~1~~ 7 which is 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole.

~~11.~~ 10 A compound of claim ~~1~~ 7 which is 5-(4-trifluoromethylphenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole.

~~12.~~ 11 A compound of claim ~~1~~ 7 which is 1-(4-bromophenyl)-5-(4-chlorophenyl)-3-(3-hydroxypropyl) pyrazole.

13. A compound of claim 1 which is sodium 8-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-5(Z)-octenoate.

14. A compound of claim 1 which is sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propanoate.

~~15.~~ A compound ~~of claim 1~~ which is 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-tert-butyl-N-hydroxypropanamide.

~~16.~~ A compound ~~of claim 1~~ which is N-carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-propanamide.

~~17.~~ A compound ~~of claim 1~~ selected from the group consisting of ~~N-carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propanamide,~~ 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-isopropylpropanamide, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-cyclohexyl-N-hydroxy-propanamide, and 3-[5-(4-chlorophenyl)-1-(4-methoxy-phenyl)-3-pyrazolyl]-N-ethyl-N-hydroxypropanamide.

~~18.~~ A compound ~~of claim 1~~ selected from the group consisting of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-phenyl-propanamide, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propylamine, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propanal, 5-(4-chlorophenyl)-3-(3-oximino-propyl)-1-(4-methoxyphenyl)-pyrazole and 3-(3-hydroxypropyl)-1-(4-methyoxyphenyl)-5-(4-tolyl)pyrazole.

19. A pharmaceutical composition for topical, oral, parenteral and aerosol administration, comprising an effective amount of a substituted pyrazole compound according to claim 1 as active ingredient dispersed in a pharmaceutically acceptable carrier.

20. The pharmaceutical composition according to claim ~~19~~ wherein said substituted pyrazole compound is capable of inhibiting both the cyclooxygenase and lipoxygenase pathways in the amount present in the composition when said composition is introduced into a mammal.

~~21.~~ 13 A method for alleviating inflammation in a mammal exhibiting an inflammatory response comprising administering to said mammal a pharmaceutical composition according to claim ~~19.~~ 31 4

~~22.~~ 14 A method for treating inflammatory conditions of skin, including psoriasis or other dermatitis, comprising administering to said mammal a pharmaceutical composition according to claim ~~19.~~ 31 1

23. A method for ~~treating myocardial~~ insufficiencies, including angina, vasospasm, infarction, comprising administering to said mammal a pharmaceutical composition comprising an amount effective against myocardial insufficiency, of a substituted pyrazole compound according to claim 1 as active ingredient, dispersed in a pharmaceutically acceptable carrier.

24. A method for treating asthma and allergic hypersensitivity diseases comprising administering to said mammal an effective amount of a pharmaceutical composition according to claim ~~19.~~ 31

25. A method for synthesizing a 1,5-diaryl-3-(omega-substituted lower alkyl)-pyrazole of claim 1 comprising reacting an arylhydrazine with a 1-aryl-(omega-substitued)-alkyl-1,3-dione containing at least 4 carbons in the alkyl chain, said reaction being carried out in a solvent that is substantially inert to said reaction conditions, and said omega-substituent being substantially inert to said reaction conditions, wherein said aryl groups are the same or different and are mono- or di-subsubstituted phenyl wherein said phenyl substituents are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, napthyl and substituted naphthyl.

89

~~26.~~ 37 A compound ~~of claim 1~~ 34 which is 3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-3-pyrazolyl]-N-hydroxy-N-methyl propanamide.

27. A compound of claim 1 31 which is 3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-3-pyrazolyl]-N-methyl-N-succinyloxypropanamide.

28. A compound of claim 1 31 which is 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N'-N'-dimethylglycinyloxy-N-methylpropanamide.

29. A compound of claim 1 31 which is N-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propyl]-N,N'-dihydroxyoxamide.

30. A compound of claim 1 31 which is N-acetyl-N-acetoxy[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propanamide.